RHOH and neoplasm: In 1998, stimulated by P. Thorpe’s work [28], our laboratory started to design a group of new bifunctional tTF fusion proteins to target procoagulatory activity selectively into the tumor vasculature and to induce tumor infarction [48,51,63,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81].